title: Nutritional Impact of Dietary Plasma Proteins in Animals Undergoing Experimental Challenge and Implications for Patients with Inflammatory Bowel Disorders: A Meta-analysis.
abstract: Studies administering plasma protein isolates (PPIs) to experimentally challenged animals have reported improvements in growth, food intake, and overall condition when compared with animals fed control diets, due in part to improvements in gut barrier function, normalization of cytokine signals, and support of enteric immune function. These and early clinical studies suggest that nutritional therapy with PPIs may similarly assist in restoring homeostasis to gut barrier function in humans experiencing mild or more acute enteropathic symptomatology such as irritable bowel syndrome and inflammatory bowel disease. This meta-analysis evaluated the ability of PPIs to promote weight gain and food intake in weanling animals, primarily piglets, after oral challenge with various enteric pathogens or bacterial toxins. MEDLINE, EMBASE, and PubMed were searched from 1980 through August 2012 for specified terms and keywords. Twenty-nine articles retrieved through this process were evaluated; 11 studies including 13 experiments were selected for inclusion in the analysis. The meta-analysis included descriptive analyses and methods for combining P values for the primary endpoint, average daily growth (ADG) at week 1, and secondary endpoints including ADG, average daily feed intake (ADFI), and gain to feed ratio (G:F) at weeks 1 and 2 and at the end of study. Primary and secondary endpoint analyses of growth (ADG, ADFI, and G:F) were significant (P < 0.01). The proinflammatory cytokines interleukin (IL) 1β, IL-6, and tumor necrosis factor α were significantly lower in animals fed dietary PPIs. Additional research in patients experiencing symptoms of enteropathy will further characterize the benefits of PPIs in clinical populations.
authors.affiliation: QED Pharmaceutical Services, Morrisville, NC;
authors.forename: Ramana
authors.initials: R
authors.lastname: Kuchibhatla
authors.affiliation: Entera Health, Inc., Cary, NC; and bryon.petschow@enterahealth.com.
authors.forename: Bryon W
authors.initials: BW
authors.lastname: Petschow
authors.affiliation: North Carolina State University, Raleigh, NC.
authors.forename: Jack
authors.initials: J
authors.lastname: Odle
authors.affiliation: Entera Health, Inc., Cary, NC; and.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Weaver
mesh_terms: D000821:Animal Feed / Q000032:analysis; D000818:Animals; D001798:Blood Proteins / Q000008:administration & dosage*; D016208:Databases, Factual; D004044:Dietary Proteins / Q000008:administration & dosage*; D004195:Disease Models, Animal; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D001798:Blood Proteins; D004044:Dietary Proteins
keywords: IBS; agrimedical; barrier function; enteropathy; immunoglobulin; inflammatory bowel disease; linear growth; plasma protein